Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KPI Therapeutics working to develop effective, safe therapies for autoimmune diseases
April 2016
SHARING OPTIONS:

KPI Therapeutics
 
Dalazatide is a novel therapy targeting autoimmune diseases utilizing a new mechanism of action. Dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel implicated in many autoimmune diseases. Dalazatide is being studied as a potential lupus therapy. Peptides from the dalazatide family also have potential as therapies for uveitis and atopic dermatitis.
 
KPI Therapeutics
206-788-4600

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.